Berber Piet

7PUBLICATIONS
65CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMolecular medicineApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 27, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment.

Nikki de Rouw, Leila-Sophie Otten, Mart P Kicken

|Oct 01, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.

Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn

|Apr 13, 2024
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.

Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos

|Apr 01, 2023
Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression.

Demy A C van den Haak, Leila-Sophie Otten, Hans J P M Koenen

|May 18, 2022
Kidney Injury in Patients Treated with Immune Checkpoint Inhibitors Does Not Meet KDIGO-AKI Criteria.

Maartje F A Verploegen, Marye J Boers-Sonderen, Berber Piet

Pageof 2